These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

320 related items for PubMed ID: 16104110

  • 1. [Clinical implications of new insights into the regulation of bone resorption].
    Lems WF, Bijlsma JW.
    Ned Tijdschr Geneeskd; 2005 Jul 23; 149(30):1664-7. PubMed ID: 16104110
    [Abstract] [Full Text] [Related]

  • 2. Osteoprotegerin and its ligand: A new paradigm for regulation of osteoclastogenesis and bone resorption.
    Aubin JE, Bonnelye E.
    Medscape Womens Health; 2000 Mar 23; 5(2):5. PubMed ID: 10792853
    [Abstract] [Full Text] [Related]

  • 3. RANKL-RANK signaling in osteoclastogenesis and bone disease.
    Wada T, Nakashima T, Hiroshi N, Penninger JM.
    Trends Mol Med; 2006 Jan 23; 12(1):17-25. PubMed ID: 16356770
    [Abstract] [Full Text] [Related]

  • 4. Evidence of a role for RANKL in the development of myeloma bone disease.
    De Leenheer E, Mueller GS, Vanderkerken K, Croucher PI.
    Curr Opin Pharmacol; 2004 Aug 23; 4(4):340-6. PubMed ID: 15251126
    [Abstract] [Full Text] [Related]

  • 5. Novel aspects on RANK ligand and osteoprotegerin in osteoporosis and vascular disease.
    Sattler AM, Schoppet M, Schaefer JR, Hofbauer LC.
    Calcif Tissue Int; 2004 Jan 23; 74(1):103-6. PubMed ID: 14523602
    [Abstract] [Full Text] [Related]

  • 6. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases.
    Hofbauer LC, Schoppet M.
    JAMA; 2004 Jul 28; 292(4):490-5. PubMed ID: 15280347
    [Abstract] [Full Text] [Related]

  • 7. [Osteoclast function is regulated by neighbouring osteoblasts. Osteoprotegerin, RAND and RANK ligand constitute a unique regulatory system for bone resorption with important pathophysiological and therapeutic aspects].
    Ueland T, Bollerslev J, Mosekilde L.
    Ugeskr Laeger; 2002 Jul 01; 164(27):3526-30. PubMed ID: 12116680
    [Abstract] [Full Text] [Related]

  • 8. Anti-RANKL therapy for inflammatory bone disorders: Mechanisms and potential clinical applications.
    Anandarajah AP, Schwarz EM.
    J Cell Biochem; 2006 Feb 01; 97(2):226-32. PubMed ID: 16240334
    [Abstract] [Full Text] [Related]

  • 9. Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system.
    Tanaka S, Nakamura K, Takahasi N, Suda T.
    Immunol Rev; 2005 Dec 01; 208():30-49. PubMed ID: 16313339
    [Abstract] [Full Text] [Related]

  • 10. [Osteoclastogenesis Inhibitory Factor (OCIF) /Osteoprotegerin (OPG) as a new therapeutic agent for osteoporosis].
    Mochizuki S, Kiyokawa A, Nagayama Y.
    Clin Calcium; 2005 Jan 01; 15(1):35-42. PubMed ID: 15632471
    [Abstract] [Full Text] [Related]

  • 11. New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL).
    Giuliani N, Colla S, Rizzoli V.
    Exp Hematol; 2004 Aug 01; 32(8):685-91. PubMed ID: 15308315
    [Abstract] [Full Text] [Related]

  • 12. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin.
    Collin-Osdoby P.
    Circ Res; 2004 Nov 26; 95(11):1046-57. PubMed ID: 15564564
    [Abstract] [Full Text] [Related]

  • 13. RANK ligand and TNF-alpha mediate acid-induced bone calcium efflux in vitro.
    Frick KK, LaPlante K, Bushinsky DA.
    Am J Physiol Renal Physiol; 2005 Nov 26; 289(5):F1005-11. PubMed ID: 15972386
    [Abstract] [Full Text] [Related]

  • 14. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling.
    Theoleyre S, Wittrant Y, Tat SK, Fortun Y, Redini F, Heymann D.
    Cytokine Growth Factor Rev; 2004 Dec 26; 15(6):457-75. PubMed ID: 15561602
    [Abstract] [Full Text] [Related]

  • 15. Osteoprotegerin and receptor activator of nuclear factor-kappaB ligand system in the early post-operative period of liver transplantation.
    Fábrega E, Orive A, García-Unzueta M, Amado JA, Casafont F, Pons-Romero F.
    Clin Transplant; 2006 Dec 26; 20(3):383-8. PubMed ID: 16824158
    [Abstract] [Full Text] [Related]

  • 16. The osteoprotegerin/osteoprotegerin ligand family: role in inflammation and bone loss.
    Yeung RS.
    J Rheumatol; 2004 May 26; 31(5):844-6. PubMed ID: 15124240
    [No Abstract] [Full Text] [Related]

  • 17. Statins modulate the levels of osteoprotegerin/receptor activator of NFkappaB ligand mRNA in mouse bone-cell cultures.
    Kaji H, Kanatani M, Sugimoto T, Chihara K.
    Horm Metab Res; 2005 Oct 26; 37(10):589-92. PubMed ID: 16278780
    [Abstract] [Full Text] [Related]

  • 18. Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: role in the interactions with receptor activator of nuclear factor kappaB ligand (RANKL) and RANK.
    Théoleyre S, Kwan Tat S, Vusio P, Blanchard F, Gallagher J, Ricard-Blum S, Fortun Y, Padrines M, Rédini F, Heymann D.
    Biochem Biophys Res Commun; 2006 Aug 25; 347(2):460-7. PubMed ID: 16828054
    [Abstract] [Full Text] [Related]

  • 19. Update on the pathogenesis of osteolysis in multiple myeloma patients.
    Giuliani N, Colla S, Rizzoli V.
    Acta Biomed; 2004 Dec 25; 75(3):143-52. PubMed ID: 15796087
    [Abstract] [Full Text] [Related]

  • 20. Circulating osteoprotegerin and soluble RANKL: do they have a future in clinical practice?
    Dovio A, Data V, Angeli A.
    J Endocrinol Invest; 2005 Dec 25; 28(10 Suppl):14-22. PubMed ID: 16550717
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.